高剂量硒对心脏手术患者术后器官功能障碍与死亡率的影响:SUSTAIN CSX随机临床试验
该多中心随机双盲安慰剂对照试验纳入1416例高危心脏手术患者,评估围术期静脉高剂量亚硒酸钠是否减少术后器官功能障碍和死亡。
要点
- 高危心脏手术患者围术期高剂量静脉亚硒酸钠未改善无器官功能障碍生存。
- 30天死亡率硒组4.2%与安慰剂组5.0%无显著差异。
- 数据不支持心脏手术患者常规围术期使用硒。
核心结论
- 在高危心脏手术患者中,围术期给予高剂量静脉亚硒酸钠未降低发病率或死亡率。
- 现有数据不支持心脏手术患者常规围术期使用硒。
研究设计与样本
- 多中心、随机、双盲、安慰剂对照试验,在德国和加拿大23个中心于2015年1月至2021年1月开展。
- 纳入成人心脏手术患者,要求欧洲心脏手术风险评估系统II预测死亡率≥5%或计划联合手术,共分析1416例。
- 患者按1:1随机接受围术期静脉高剂量亚硒酸钠(体外循环前2000 μg/L,术后立即2000 μg/L,ICU每日1000 μg/L,最长10天)或安慰剂。
主要发现
- 两组安全性结局无差异。
临床怎么用
- 对于高危心脏手术患者,不应仅基于降低器官功能障碍或死亡风险的预期而常规围术期补充高剂量硒。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Selenium contributes to antioxidative, anti-inflammatory, and immunomodulatory pathways, which may improve outcomes in patients at high risk of organ dysfunctions after cardiac surgery. OBJECTIVE: To assess the ability of high-dose intravenous sodium selenite treatment to reduce postoperative organ dysfunction and mortality in cardiac surgery patients. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, randomized, double-blind, placebo-controlled trial took place at 23 sites in Germany and Canada from January 2015 to January 2021. Adult cardiac surgery patients with a European System for Cardiac Operative Risk Evaluation II score-predicted mortality of 5% or more or planned combined surgical procedures were randomized. INTERVENTIONS: Patients were randomly assigned (1:1) by a web-based system to receive either perioperative intravenous high-dose selenium supplementation of 2000 μg/L of sodium selenite prior to cardiopulmonary bypass, 2000 μg/L immediately postoperatively, and 1000 μg/L each day in intensive care for a maximum of 10 days or placebo. MAIN OUTCOMES AND MEASURES: The primary end point was a composite of the numbers of days alive and free from organ dysfunction during the first 30 days following cardiac surgery. RESULTS: A total of 1416 adult cardiac surgery patients were analyzed (mean [SD] age, 68.2 [10.4] years; 1043 [74.8%] male). The median (IQR) predicted 30-day mortality by European System for Cardiac Operative Risk Evaluation II score was 8.7% (5.6%-14.9%), and most patients had combined coronary revascularization and valvular procedures. Selenium did not increase the number of persistent organ dysfunction-free and alive days over the first 30 postoperative days (median [IQR], 29 [28-30] vs 29 [28-30]; P = .45). The 30-day mortality rates were 4.2% in the selenium and 5.0% in the placebo group (odds ratio, 0.82; 95% CI, 0.50-1.36; P = .44). Safety outcomes did not differ between the groups. CONCLUSIONS AND RELEVANCE: In high-risk cardiac surgery patients, perioperative administration of high-dose intravenous sodium selenite did not reduce morbidity or mortality. The present data do not support the routine perioperative use of selenium for patients undergoing cardiac surgery. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02002247.
引用
- Stoppe C, McDonald B, Meybohm P, et al. Effect of High-Dose Selenium on Postoperative Organ Dysfunction and Mortality in Cardiac Surgery Patients: The SUSTAIN CSX Randomized Clinical Trial. JAMA Surg. 2023. PMID: 36630120. doi:10.1001/jamasurg.2022.6855
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。